JPMorgan maintained its Overweight rating on Mankind Pharma Ltd (MANKIND:IN) and increased the price target from INR3,000.00 ...

The funding issue was oversubscribed by 2.7 times and facilitated by InCred, with the company being valued at INR 1,000 crore (around USD 120 million).

Mankind Pharma Ltd.'s share price declined more than 5% during early trade on Friday after the company's third-quarter ...

Mankind's revenue from operations rose to Rs 3,230 crore in Q3FY25, a 24 per cent Y-o-Y rise from Rs 2,607 crore reported in ...

Net profit of mankind Pharma declined by 16.2% to ₹380.2 crore compared with ₹453.8 crore in the corresponding quarter of the ...

Macquarie has lowered its FY25/26/27 earnings estimates by 17 percent, 24 percent, and 17 percent, respectively, due to ...

The Board of Directors of Mankind Pharma Limited, at its meeting held today have approved the financial results of the ...

NDTV Profit tracks what analysts are saying about various stocks and sectors. Here are the analyst calls to keep an eye out ...

Mankind Pharma's net profit fell 16.5% to Rs 384 crore in Q3 FY25, while revenue rose 24% to Rs 3,230 crore. The company's ...

Mankind Pharma's Q3 net profit was impacted by the $1.6 billion acquisition of Bharat Serums and Vaccines (BSV), which came ...

No Data For Bulk Deal. *Involves transaction of at least 0.5% of the listed shares of a company. What was Mankind Pharma Ltd share price previously? Mankind Pharma Ltd share price was down by -2. ...

On Monday, JPMorgan maintained its Overweight rating on Mankind Pharma Ltd (MANKIND:IN) and increased the price target from INR3,000.00 to INR3,150.00. The adjustment follows the company's third ...